BioSpace News Archive

PAVmed Inc., a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, announced that its majority-owned digital health subsidiary Veris Health Inc., has commercially launched its Veris Cancer Care Platform™.

Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced positive topline results from the completed Phase 1b Callisto trial and the enrollment of the first subject in the Carpo Phase 2a trial.

Maze Therapeutics today announced the completion of its first-in-human clinical trial designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and food effect of MZE001 in healthy volunteers.

Kaiser Permanente members who were more physically active prior to being diagnosed with COVID-19 had a lower risk of severe outcomes, according to research published Dec. 15, 2022, in the American Journal of Preventive Medicine.

IRLAB Therapeutics AB, a company discovering and developing novel treatments for the most troublesome symptoms of Parkinson’s disease, announced that the company will present at the DNB Nordic Healthcare Conference on Thursday, December 15, 2022, in Oslo, Norway.

Providence Medical Technology, Inc. announced that the U.S. Food and Drug Administration has cleared its CAVUX® Facet Fixation System for a new indication.

Immunocore is awarded the Prix Galien France award for KIMMTRAK Treatment for unresectable or metastatic uveal melanoma, a rare and aggressive form of cancer affecting the eye.

Velocity Clinical Research (“Velocity”), the leading integrated research site organization, today announces its acquisition of Meridian Clinical Research for an undisclosed amount.

Metagenomi Announces Publication of Data in Nature Communications Describing Novel, Ultra-Small Nucleases for Gene Editing.

Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women’s health and treatment of female stress urinary incontinence, today announced the completion of final 12-month post-treatment follow-up visits in its landmark U.S. PURSUIT clinical trial for the treatment of stress urinary incontinence (SUI) in women.